Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. (ACRX) on September 23, 2019. The report discloses the entry into a material definitive agreement. Note: The request metadata lists "TALPHERA, INC.", but the filing text explicitly identifies the registrant as AcelRx Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses solely on a contractual amendment and does not contain financial statements or performance metrics.
Material Changes
Effective September 23, 2019, AcelRx Pharmaceuticals, Inc. amended its supply agreement with SpecGX LLC. The primary change is the extension of the agreement term through December 31, 2022.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the specific agreement amendment.
Investor Verification Checklist
- Verify the full terms of the amended supply agreement with SpecGX LLC.
- Confirm the operational impact of extending the supply agreement through 2022.
- Review subsequent filings for any financial implications of this extended term.